A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants
暂无分享,去创建一个
[1] A. Kiss,et al. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Funda Meric-Bernstam,et al. Personalized cancer therapy—leveraging a knowledge base for clinical decision-making , 2018, Cold Spring Harbor molecular case studies.
[3] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[4] Rajendu Srivastava,et al. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs , 2016, Journal of oncology practice.
[5] Corinna Ernst,et al. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics , 2018, BMC Medical Genomics.
[6] M. Tuchman,et al. Identification of ‘private’ mutations in patients with ornithine transcarbamylase deficiency , 1997, Journal of Inherited Metabolic Disease.
[7] Charles Swanton,et al. My Cancer Genome: a unified genomics and clinical trial portal , 2012 .
[8] J Jack Lee,et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[10] S. Ellard,et al. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. , 2010, Genetic testing and molecular biomarkers.
[11] Li Ding,et al. Database of evidence for precision oncology portal , 2018, Bioinform..
[12] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[13] Harry Hochheiser,et al. HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model , 2019, Journal of Biomedical Informatics.
[14] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[15] S. Patterson,et al. Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data , 2019, npj Precision Oncology.
[16] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[17] Md Abu Shufean,et al. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. , 2017, Cancer research.
[18] Vincent Ferretti,et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial , 2013, International journal of cancer.
[19] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[20] D. M. Hyman,et al. Oncologist use and perception of large panel next-generation tumor sequencing , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] R. Jones,et al. To be Therapeutic. , 1967 .
[22] Funda Meric-Bernstam,et al. Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. , 2019, JCO clinical cancer informatics.
[23] Jeremy L Warner,et al. Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[25] Gil Alterovitz,et al. SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. , 2018, JCO precision oncology.
[26] Razelle Kurzrock,et al. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. , 2016, JAMA oncology.
[27] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.
[28] Christine M. Micheel,et al. The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome12 , 2016, Translational oncology.
[29] Fei Ye,et al. My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information , 2016, CRI.
[30] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[31] M. Krzyzanowska,et al. Off-label use of cancer drugs: a benchmark is established. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Marcin Imielinski,et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations , 2016, J. Am. Medical Informatics Assoc..
[33] E. Mardis,et al. Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Richard L Schilsky,et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Deborah Schrag,et al. Precision Oncology: Who, How, What, When, and When Not? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[36] Karol Sikora,et al. Personalized cancer therapy. , 2005, Personalized medicine.
[37] R. Altman,et al. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. , 2005, Methods in molecular biology.
[38] M. Levy,et al. Integrating cancer genomic data into electronic health records , 2016, Genome Medicine.
[39] Li Ding,et al. Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.
[40] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[41] Riccardo Bellazzi,et al. A Semi-supervised Learning Approach for Pan-Cancer Somatic Genomic Variant Classification , 2019, AIME.
[42] L. Hayden,et al. Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2011 .
[43] Niranjan Nagarajan,et al. ConsensusDriver Improves upon Individual Algorithms for Predicting Driver Alterations in Different Cancer Types and Individual Patients. , 2018, Cancer research.
[44] Shinichiro Suzuki,et al. A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing , 2019, Scientific Reports.
[45] Peng Gao,et al. Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. , 2019, Biochimica et biophysica acta. Reviews on cancer.
[46] Jean Muller,et al. Identification of 28 novel mutations in the Bardet–Biedl syndrome genes: the burden of private mutations in an extensively heterogeneous disease , 2010, Human Genetics.
[47] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[48] Anuradha Lakshminarayana,et al. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies , 2016, Human Genomics.
[49] David Bourque,et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database , 2019, JAMA.
[50] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[51] Yuquan Wei,et al. The Therapeutic Target Database: an Internet resource for the primary targets of approved, clinical trial and experimental drugs , 2011, Expert opinion on therapeutic targets.
[52] Yves Sznajer,et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[53] Subha Madhavan,et al. A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants , 2018, bioRxiv.
[54] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[55] Kenna R Mills Shaw,et al. Clinical Use of Precision Oncology Decision Support. , 2017, JCO precision oncology.